We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The NIH’s National Institutes of Allergy and Infectious Diseases (NIAID) has launched a phase 3 trial of Gilead Sciences’ remdesivir with Merck’s anti-inflammatory drug Rebif (interferon-beta-1a) for the treatment of hospitalized COVID-19 patients. Read More
As concerns mount over the FDA coming under undue pressure to approve a COVID-19 vaccine, FDA Commissioner Stephen Hahn said again yesterday that the agency won’t take any shortcuts. Read More
Massachusetts-based Partner Therapeutics has secured a $35 million contract from the Department of Defense for clinical trials of inhaled Leukine (sargramostim) for the treatment of COVID-19 patients with acute hypoxemia. Read More
Novavax has announced preliminary data from a phase 1 trial of its COVID-19 vaccine NVX-CoV2373 in Australia that showed the vaccine generated a strong immune response. Read More
The National Institutes of Health (NIH) launched two clinical trials yesterday of Eli Lilly’s experimental monoclonal antibody LY-CoV555 for the treatment for COVID-19 patients. Read More